- MGI Announces Price and Early Access Customer of MGISEQ-T7
- MGI Announces Milestone of 1,000 Sequencers Installed and Opens Early Access Program for Groundbreaking Ultra-High-Throughput Sequencer, MGISEQ-T7
- Three BGI Researchers Listed as Highly Cited Researchers
- China National GeneBank and Macquarie University Deepen Cooperation in Synthetic Biology
- Establishment of the first Macaca fascicularis gut microbiome gene catalog
- Establishing the first gene catalogue of Sprague-Dawley rat gut metagenome based on the BGISEQ-500 platform
- The international Sc2.0 Project is on track to build the world’s first synthetic yeast genome
- Avian-specific conserved genomic elements play important regulatory roles in the macroevolution of avian-specific features
- Leading Health Organizations in Canada and China Teaming up to Accelerate Precision Medicine
- World’s largest genomic organisation to collaborate with leading Queensland researchers
- Ranomics Partners with BGI to Classify Variants of Unknown Significance
- BGI and UW collaborate on precision medicine development
- Meet The Chinese Company That Wants To Be The Intel Of Personalized Medicine
- Chinese innovation : BGI’s code for success
- Prof. Huanming Yang to Receive Membership from Royal Danish Academy of Sciences and Letters
- UW, Chinese genomics group forge new partnership to advance biomedical research
Tel: +86-755-36307212Email: firstname.lastname@example.org
The goal of the collaboration is to create a next-generation super exome, using Agilent’s SureSelect technology. The super exome incorporates sequence regions believed to be more informative for specific human populations. BGI is the largest genome sequencing center in Asia and one of the largest genomics research centers in the world.
“BGI aims to develop research collaborations and provide support to scientists all over the world,” said Hui Jiang, associate director of the Science and Technology Department at BGI. “Together with Agilent’s expertise, we can create more precise and accurate technology that can be deployed in large-scale research to better understand complex diseases, which may have differences between ethnicities.”
As part of this collaboration, BGI has selected to use Agilent’s comprehensive portfolio of solutions for genomics research and next-generation sequencing tools. These include Agilent’s SureSelect target-enrichment system and Agilent’s 2100 bioanalyzers. Additionally, Agilent will grant BGI early access to newly developed tools for the sequencing space.
“Agilent has a comprehensive portfolio of market-leading solutions for genomics research,” said Robert Schueren, vice president and general manager of Agilent’s genomics business. “This partnership with BGI will not only add to this portfolio, but also further Agilent’s mission to build products that enable life sciences discoveries and develop solutions that improve the human condition."
BGI and Agilent have been working closely together over the years. Previously, BGI used Agilent’s technologies to streamline and enhance the throughput of BGI’s next-generation sequencing workflow. In China, BGI became the country’s first certified SureSelect XT service provider.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 18,700 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at www.agilent.com.